Zeumed x ULAM Labs

Designing digital health products that can be adopted, funded, and scaled

Zeumed and ULAM Labs partner to help digital health and medtech teams design products that make sense clinically, technically, and commercially.

We work with founders and scale-ups who need more than great software: they need a clear route through payer decision-making, procurement, and funding, without discovering too late that key assumptions don’t hold.

Why this Partnership exists:

Many digital health products work well in pilots, but struggle to move beyond them. Reasons include:

unclear or unrealistic funding routes;
evidence that doesn’t match what decision-makers need;
product designs that don’t fit real clinical workflows or purchasing constraints.

These issues are rarely about effort or quality. They arise because commercial, clinical, and technical decisions are often made separately, and too late.

Our partnership with ULAM Labs, a software development company specialising in the delivery of custom software solutions in healthcare, exists to address that gap early - before product choices become costly to change.

An integrated economic and technical design approach

In institutional healthcare markets, adoption depends on how products fit within funding, procurement, and care-delivery structures. Clinical value and technical performance are essential, but not sufficient on their own.

Through a joint Zeumed x ULAM Labs approach, economic viability, clinical use-case design, and technical architecture are developed in parallel.

Assumptions about who pays, how value is assessed, and what evidence is required are reflected directly in product scope, data capture, and system design, rather than addressed retrospectively.

The aim is straightforward: reduce the risk that a product needs to be rethought once it reaches payers, providers, or procurement teams.

How the engagement is structured

Clear, practical, and focused on real decisions

We start with a single conversation involving both ULAM Labs and Zeumed.

We align on:

what the product is intended to change in practice;
who needs to back it for adoption to occur;
and what that implies for product design and data from the outset.

We then develop a tailored plan.

ULAM Labs leads product design and build. Zeumed works alongside this to ensure the product, evidence, and commercial pathway remain aligned.

What this achieves

Teams working through this approach typically gain:

Earlier clarity on commercial viability
Fewer late-stage surprises
A stronger story for investors and partners
A product designed for real systems

Who is this for

This partnership is suited to teams who:

are building digital health or medtech products intended for institutional buyers;

are moving from concept to pilot, or from pilot to scale;

need clarity on funding, pricing or reimbursement routes;

and want product decisions to stand up to payer, provider, and investor scrutiny.